SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 ...
PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations Literature searches were conducted in MEDLINE (via PubMed) and EMBASE to identify studies published between January ...
FDA Approves PD-L1 Companion Diagnostic in Triple-Negative Breast Cancer This past Friday, Agilent Technologies announced it has received approval by the FDA for the use of PD-L1 IHC 22C3 pharmDx as ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations Four programmed death ligand 1 (PD-L1) immunohistochemistry assays (28-8, 22C3, SP263, and SP142) have been approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results